The Frc–Oxc Pathway in Microbial Oxalate Metabolism and Its Therapeutic Potential for Calcium Oxalate Kidney Stones

Gut microbial oxalate degradation has emerged as a potential strategy for reducing hyperoxaluria and calcium oxalate kidney stone risk. Among microbial oxalate-degrading systems, the OxlT–Frc–Oxc pathway is one of the best-characterized routes because it couples oxalate catabolism to membrane transport and bacterial energy conservation. Frc activates oxalate by transferring CoA from formyl-CoA to oxalate, whereas Oxc, a thiamine-diphosphate-dependent enzyme, decarboxylates oxalyl-CoA to formyl-CoA and CO2, allowing pathway cycling. Published sequence-mining studies have identified more than 1300 putative OXC homologs distributed across seven major clusters, indicating that oxalate-degradation capacity is broader than Oxalobacter formigenes alone. However, clinical translation remains inconsistent. Recent human colonization and microbiome studies show that O. formigenes administration can reduce urinary oxalate in some individuals, but response depends on colonization stability, baseline oxalate-degrading gene abundance, diet, antibiotic exposure, and intestinal niche conditions. This review synthesizes biochemical, structural, functional, ecological, and therapeutic evidence for the Frc–Oxc pathway and discusses why gene carriage alone does not guarantee in vivo oxalate degradation. Finally, the Oxalate Niche Index (ONI) is considered as a conceptual framework for integrating genetic capacity, pathway activity, niche permissiveness, ecological persistence, and inhibitory pressure in future microbiome-based strategies for hyperoxaluria and calcium oxalate kidney stone disease.